Cargando…

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

AIM: In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II) and chronic systolic heart failure (HF). The pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dawn, Wilson, Koo, Akehurst, Ron, Cowie, Martin R, Zannad, Faiez, Krum, Henry, van Veldhuisen, Dirk J, Vincent, John, Pitt, Bertram, McMurray, John J V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215293/
https://www.ncbi.nlm.nih.gov/pubmed/24993605
http://dx.doi.org/10.1136/heartjnl-2014-305673
_version_ 1782342066382045184
author Lee, Dawn
Wilson, Koo
Akehurst, Ron
Cowie, Martin R
Zannad, Faiez
Krum, Henry
van Veldhuisen, Dirk J
Vincent, John
Pitt, Bertram
McMurray, John J V
author_facet Lee, Dawn
Wilson, Koo
Akehurst, Ron
Cowie, Martin R
Zannad, Faiez
Krum, Henry
van Veldhuisen, Dirk J
Vincent, John
Pitt, Bertram
McMurray, John J V
author_sort Lee, Dawn
collection PubMed
description AIM: In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II) and chronic systolic heart failure (HF). The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain. METHODS AND RESULTS: Results from the EMPHASIS-HF trial were used to develop a discrete-event simulation model estimating lifetime direct costs and effects (life years and quality-adjusted life years (QALYs) gained) of the addition of eplerenone to standard care among patients with chronic systolic HF and mild symptoms. Eplerenone plus standard care compared with standard care alone increased lifetime direct costs per patient by £4284 for the UK and €7358 for Spain, with additional quality-adjusted life expectancy of 1.22 QALYs for the UK and 1.33 QALYs for Spain. Mean lifetime costs were £3520 per QALY in the UK and €5532 per QALY in Spain. Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain). CONCLUSIONS: By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.
format Online
Article
Text
id pubmed-4215293
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42152932014-11-13 Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms Lee, Dawn Wilson, Koo Akehurst, Ron Cowie, Martin R Zannad, Faiez Krum, Henry van Veldhuisen, Dirk J Vincent, John Pitt, Bertram McMurray, John J V Heart Heart Failure and Cardiomyopathies AIM: In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II) and chronic systolic heart failure (HF). The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain. METHODS AND RESULTS: Results from the EMPHASIS-HF trial were used to develop a discrete-event simulation model estimating lifetime direct costs and effects (life years and quality-adjusted life years (QALYs) gained) of the addition of eplerenone to standard care among patients with chronic systolic HF and mild symptoms. Eplerenone plus standard care compared with standard care alone increased lifetime direct costs per patient by £4284 for the UK and €7358 for Spain, with additional quality-adjusted life expectancy of 1.22 QALYs for the UK and 1.33 QALYs for Spain. Mean lifetime costs were £3520 per QALY in the UK and €5532 per QALY in Spain. Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain). CONCLUSIONS: By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective. BMJ Publishing Group 2014-11-01 2014-07-03 /pmc/articles/PMC4215293/ /pubmed/24993605 http://dx.doi.org/10.1136/heartjnl-2014-305673 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Heart Failure and Cardiomyopathies
Lee, Dawn
Wilson, Koo
Akehurst, Ron
Cowie, Martin R
Zannad, Faiez
Krum, Henry
van Veldhuisen, Dirk J
Vincent, John
Pitt, Bertram
McMurray, John J V
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title_full Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title_fullStr Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title_full_unstemmed Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title_short Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
title_sort cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215293/
https://www.ncbi.nlm.nih.gov/pubmed/24993605
http://dx.doi.org/10.1136/heartjnl-2014-305673
work_keys_str_mv AT leedawn costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT wilsonkoo costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT akehurstron costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT cowiemartinr costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT zannadfaiez costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT krumhenry costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT vanveldhuisendirkj costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT vincentjohn costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT pittbertram costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms
AT mcmurrayjohnjv costeffectivenessofeplerenoneinpatientswithsystolicheartfailureandmildsymptoms